血管内支架治疗恶性肿瘤引起的上腔静脉综合征疗效分析

Endovascular stenting for the treatment of superior vena cava syndrome caused by malignant tumors:analysis of its curative effect

目的探讨血管内支架治疗恶性肿瘤引起的上腔静脉综合征(SVCS)的临床疗效。方法对2015年5月至2018年5月32例进行血管内支架治疗SVCS患者的临床资料进行回顾性分析。结果 31例患者手术成功,植入46枚支架,技术成功率96.9%,其中15例SVCS患者植入支架2枚,16例植入支架1枚。术后症状完全缓解11例,部分缓解19例,无效1例,总缓解率96.8%。26例患者随访3～10个月,23例随访期间死亡,平均生存期3.5个月, 4例患者随访期间症状复发。结论血管内支架治疗恶性肿瘤引起的上腔静脉综合征创伤小,可快速缓解症状,提高肿瘤晚期患者的生存质量,可作为治疗SVCS的首选治疗手段。

Objective To evaluate the safety and effectiveness of endovascular stenting in treating superior vena cava syndrome(SVCS) caused by malignant tumors. Methods Between May 2015 and May2018, a total of 32 patients with SVCS caused by malignant tumor received endovascular stent therapy. The clinical data were retrospectively analyzed. Results Successful implantation of stent in the superior vena cava was accomplished in all 31 patients, and a total of 46 stents were implanted, the technical success rate was 96.9%. Among the 31 patients, 15 patients received 2 stents and 16 patients received one stent. After stent implantation, complete remission of symptoms was obtained in 11 patients, partial remission of symptoms in 19 patients, and ineffective treatment in one patient. The overall remission rate was 96.8%.Twenty-six patients were followed up for 3-10 months. During the follow-up period 23 patients died. The mean survival time was 3.5 months. During follow-up period recurrence of SVCS symptoms occurred in 4 patients. Conclusion In treating SVCS caused by malignant tumors, endovascular stenting is less invasive,it can quickly relieve symptoms and improve the quality of life of patients with advanced tumor. This therapy can be used as the first choice in the treatment of SVCS.